Live Wire Reporter

2017 FDA approved listing of cancer Oncology agents Hong Kong Wholesalers

2017 FDA approved listing of cancer Oncology agents Hong Kong Wholesalers

Drugs Approved in 2017

Alunbrig (brigatinib); Ariad Pharmaceuticals; For the treatment of advanced ALK-positive metastatic non-small cell lung cancer, Approved April 2017

Bavencio (avelumab); EMD Serono/Pfizer; For the treatment of Merkel cell carcinoma, Approved March 2017

Imfinzi (durvalumab); AstraZeneca; For the treatment of advanced or metastatic urothelial carcinoma, Approved May 2017

Kisqali (ribociclib); Novartis; For the treatment of breast cancer, Approved March 2017

Nerlynx (neratinib); Puma Biotech; For the treatment of HER2 breast cancer, Approved July 2017

Rydapt (midostaurin); Novartis; For the treatment of FLT3 positive acute myeloid leukemia and mastocytosis , Approved April 2017

Xermelo (telotristat ethyl); Lexicon Pharmaceuticals; For the treatment of carcinoid syndrome diarrhea, Approved February 2017

Zejula (niraparib);

Tesaro; For the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer , Approved March 2017

Drugs Approved in 2016

Cabometyx (cabozantinib); Exelixis; For the treatment of advanced renal cell carcinoma, Approved April 2016

Keytruda (pembrolizumab); Merck; For the treatment of head and neck squamous cell cancer, Approved August 2016

Lartruvo (olaratumab); Eli Lilly; For the treatment of soft tissue sarcoma, Approved October 2016

Lenvima (lenvatinib); Eisai; For the treatment of advanced renal cell carcinoma, Approved May 2016

Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of classical Hodgkin lymphoma, Approved May 2016

Rubraca (rucaparib); Clovis Oncology; For the treatment of advanced ovarian cancer in women with deleterious germline or somatic BRCA mutation, Approved December 2016

Sustol (granisetron); Heron Therapeutics; For the prevention of chemotherapy-induced nausea and vomiting, Approved August 2016

Syndros (dronabinol oral solution); Insys Therapeutics; For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy, Approved July 2016

Tecentriq (atezolizumab); Genentech; For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer, Approved May 2016

Venclexta (venetoclax); AbbVie; For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016

Drugs Approved in 2015

Alecensa (alectinib);

Roche; For the treatment of ALK-positive, metastatic non-small cell lung cancer , Approved December 2015

Cotellic (cobimetinib) ; Genentech; For the treatment of BRAF V600E or V600K melanoma, Approved November 2015

Darzalex (daratumumab); Janssen Biotech; For the treatment of multiple myeloma, Approved November 2015

Empliciti (elotuzumab); Bristol-Myers Squibb; For the treatment of patients with multiple myeloma who have received prior therapies, Approved November 2015

Farydak (panobinostat); Novartis; For the treatment of multiple myeloma, Approved February 2015

Ibrance (palbociclib); Pfizer; For the treatment of ER-positive, HER2-negative breast cancer, Approved February 2015

Imlygic (talimogene laherparepvec) ; Amgen; For the treatment of unresectable recurrent melanoma, Approved October 2015

Keytruda (pembrolizumab); Merck; For the treatment of PD-L1 positive advanced non-small cell lung cancer, Approved October 2015

Lenvima (lenvatinib); Eisai; For the treatment of thyroid cancer, Approved February 2015

Lonsurf (trifluridine and tipiracil); Taiho Oncology; For the treatment of metastatic colorectal cancer , Approved September 2015

Ninlaro (ixazomib); Millennium Pharmaceuticals; For the treatment of multiple myeloma, Approved November 2015

Odomzo (sonidegib); Novartis; For the treatment of locally advanced basal cell carcinoma, July 2015

Onivyde (irinotecan liposome injection); Merrimack; For the treatment of metastatic pancreatic cancer following gemcitabine-based therapy, Approved October 2015

Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of advanced renal cell carcinoma, Approved November 2015

Portrazza (necitumumab); Eli Lilly; For the treatment of metastatic squamous non-small cell lung cancer, Approved November 2015

Tagrisso (osimertinib); AstraZeneca; For the treatment of EGFR T790M mutation positive non-small cell lung cancer , Approved November 2015

Unituxin (dinutuximab); United Therapeutics; For the treatment of pediatrics with high-risk neuroblastoma, Approved March 2015

Varubi (rolapitant); Tesaro; For the prevention of delayed nausea and vomiting associated with chemotherapy, Approved September 2015

Vistogard (uridine triacetate); Wellstat Therapeutics; For the emergency treatment of patients with a fluorouracil or capecitabine overdose, Approved December 2015

Yondelis (trabectedin); Janssen; For the treatment of liposarcoma or leiomyosarcoma, Approved October 2015

Drugs Approved in 2014

Akynzeo (netupitant and palonosetron); Helsinn; For the prevention of chemotherapy-induced nausea and vomiting, Approved October 2014

Beleodaq (belinostat); Spectrum Pharmaceuticals; For the treatment of relapsed or refractory peripheral T-cell lymphoma, Approved July 2014

Blincyto (blinatumomab); Amgen; For the treatment of Philadelphia chromosome-negative relapsed /refractory B cell precursor acute lymphoblastic leukemia, Approved December 2014

Cyramza (ramucirumab); Eli Lilly; For the treatment of gastric cancer, Approved April 2014

Imbruvica (ibrutinib); Pharmacyclics; For the treatment of chronic lymphocytic leukemia and Waldenstrom macroglobulinemia, Approved February 2014

Keytruda (pembrolizumab); Merck; For the treatment of unresectable or metastatic melanoma, Approved September 2014

As globally renowned free trade port, HK enjoys advanced finance, logistics and trade system. In addition, the latest cancer drugs in the world appear in its market several years earlier than Chinese mainland. As for drugs which have appeared in the market earlier like Herceptin against breast cancer, its price in HK is nearly RMB 10,000 cheaper than that in Chinese mainland. New drugs appear in the HK market nearly as fast as that in Europe and America, together with its relatively low price, so a large number of cancer patients in Chinese mainland have been attracted to seek for drugs in HK.

As reported, the majority of cancer drugs in drugstores and drug market in HK have been purchased by people from Chinese mainland. In addition, as shown by drug import and export license from official website anticancerdrugstore.com of anti cancer drug wholesaler (Ghitai Pharmaceutical Limited) registered by HK government, the latest drug against ovarian cancer Zejula (niraparib) which this license has applied for import, is exactly exported to some patient in Jiangsu Province of Chinese mainland. 

Ghitai Pharmaceutical Limited have been dealing in medicines and Pharmaceutical distributor for more than 30 years. We are an authorized wholesaler which has been duly licensed in accordance with the laws of Hong Kong (Licence No.30/2A/2014).

Ghitai Pharmaceutical Limited specialize in the import, export and sale of new medicines and pharmaceutical products for all major chronic diseases including various types of cancer. Besides serving customers in Hong Kong, we also provide high quality service to customers in Mainland China and around the world. We serve a wide range of customers including hospitals, clinics, doctors, pharmacies, individual customers and biotech companies/institutes.

An established wholesaler of medicines and pharmaceutical products

Reliability: As a fully licensed dealer who is subject to stringent supervision by government departments, we deal in products which meet internationally recognized health and safety standards.

For information on drug stock and drug prices, please contact below.

Media Contact
Company Name: Ghitai Pharmaceutical Limited
Contact Person: Hkghitai
Email: Send Email
Phone: +852-23843951
Address:Unit 10B, 4th Floor, Tower A, Hung Hom Commercial Center
Country: HongKong
Website: http://www.anticancerdrugstore.com